If You Invested in Telix Pharmaceuticals Ltd ADR (TLX)

Telix Pharmaceuticals Limited (TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. According to company disclosures, Telix concentrates on oncology and rare diseases, aiming to address significant unmet medical needs with products that combine targeted radiation with advanced imaging in a precision medicine framework. Telix is listed on both the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

The company is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. This global footprint supports Telix’s clinical development programs and commercial activities across multiple major healthcare markets.

Core focus: radiopharmaceuticals for cancer and rare diseases

Telix describes itself as developing a portfolio of clinical and commercial stage products in radiopharmaceuticals. Radiopharmaceuticals are drugs that contain radioisotopes and are used either for imaging (diagnostic) or for targeted radiation treatment (therapeutic). Telix’s activities span both areas, with products and candidates designed for precision imaging and for delivering radiation directly to disease sites.

Company information states that Telix is focused on therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. These technologies are intended to support more accurate detection, characterization, and treatment planning in conditions such as prostate cancer, kidney cancer, brain tumors, bone metastases, and other oncology indications, as well as certain rare diseases.

Commercial portfolio

Telix reports that it is developing and commercializing multiple products that have obtained marketing authorizations in various jurisdictions:

• Illuccix (kit for the preparation of gallium-68 (68Ga) gozetotide injection), which Telix describes as its first generation PSMA-PET imaging agent, has been approved in multiple markets globally. It is used for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer in approved indications.
• Gozellix (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. Food and Drug Administration (FDA). Company announcements note that Gozellix is a PSMA-PET imaging agent for prostate cancer, with features such as a longer shelf life and extended distribution radius compared with existing gallium-based products, and that it has received a permanent Healthcare Common Procedure Coding System (HCPCS) Level II code and Transitional Pass-Through (TPT) payment status from the U.S. Centers for Medicare & Medicaid Services (CMS).
• Telix also reports that its osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun, is approved in 32 European countries and Mexico.
• The company states that its miniaturized surgical gamma probe, SENSEI, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has obtained a Conformité Européenne (CE) Mark for use in the European Economic Area.

Telix has indicated that, apart from these products, no other Telix product has received a marketing authorization in any jurisdiction.

Precision medicine and PSMA imaging franchise

Company disclosures highlight a substantial focus on prostate cancer imaging through PSMA-targeted PET agents. Telix notes that its prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix), has been approved by the FDA and in multiple markets globally. Gozellix is described as a next-generation PSMA-PET imaging agent for prostate cancer, with reimbursement support in the U.S. through CMS TPT status and a dedicated HCPCS code.

Telix has also announced the BiPASS (Biopsy of the Prostate Avoidance Stratification Study) Phase 3 clinical trial, which is designed to evaluate whether combining MRI and PSMA-PET imaging with Illuccix and Gozellix can improve diagnostic performance in prostate cancer and potentially reduce the need for invasive biopsies. This reflects the company’s stated goal of expanding indications for its PSMA imaging agents beyond their existing approved uses.

Key pipeline programs in imaging

In addition to its commercial products, Telix describes a number of investigational PET imaging candidates in oncology:

• TLX101-CDx (Pixclara), an 18F-floretyrosine PET imaging candidate for glioma, a rare and life-threatening brain cancer. Telix has reported that it is working on a New Drug Application (NDA) resubmission to the U.S. FDA, and that an Expanded Access Program remains active. TLX101-CDx has not received marketing authorization in any jurisdiction.
• TLX250-CDx (Zircaix), an investigational PET agent for the diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most common kidney cancer subtype. Telix states that TLX250-CDx targets carbonic anhydrase IX (CAIX), a protein expressed on a high proportion of ccRCC cells, and that its pivotal Phase 3 ZIRCON trial met all primary and secondary endpoints, showing predefined sensitivity, specificity, and positive predictive value. TLX250-CDx has not received marketing authorization in any jurisdiction, and Telix has discussed regulatory interactions with the FDA and plans for marketing authorization applications in regions such as Europe.
• Telix also refers to other PET imaging candidates in its pipeline that may be evaluated in combination with external beam radiation therapy (EBRT) through a collaboration with Varian, a Siemens Healthineers company.

Therapeutic radiopharmaceutical pipeline

Telix’s disclosures describe a therapeutics business focused on targeted radiopharmaceutical treatments for cancer. Key investigational therapeutic candidates mentioned by the company include:

• TLX591 (177Lu-rosopatamab tetraxetan), described as Telix’s lead prostate cancer therapy candidate, being evaluated in the ProstACT Global Phase 3 trial.
• TLX250 (177Lu-DOTA-girentuximab), a therapy candidate for advanced metastatic ccRCC, with trials such as LUTEON and STARLITE-1 referenced by the company.
• TLX101 (131I-iodofalan, or 131I-IPA), an investigational therapy for recurrent glioblastoma, being studied in the IPAX-BrIGHT trial.
• TLX090 (153Sm-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone metastasis. Telix has announced the SOLACE Phase 1 trial to evaluate pharmacokinetics, dosimetry, safety, and pain palliation in patients with advanced cancer that has metastasized to the bony skeleton. TLX090 has not received marketing authorization in any jurisdiction.
• TLX400 (177Lu-DOTAGA.Glu.(FAPi)2), a Fibroblast Activation Protein (FAP)–targeting therapy candidate, with early clinical data reported in subjects with advanced sarcoma.

These therapeutic programs reflect Telix’s stated strategy to build a portfolio that spans both diagnostic imaging and targeted radiotherapy, often within the same disease areas, consistent with a theranostic approach.

Manufacturing and infrastructure

Telix has reported progress in building internal manufacturing capabilities through Telix Manufacturing Solutions (TMS). Company announcements state that facilities in North Melbourne (Australia) and Yokohama (Japan) have been granted radiation licenses for a broad range of clinically and commercially important medical isotopes and are being prepared for operational readiness. Telix also refers to partnerships and technologies that support cyclotron-based production of radiopharmaceuticals, such as systems used for Gozellix production.

Regulatory and capital markets profile

As a foreign private issuer in the U.S., Telix files reports with the U.S. Securities and Exchange Commission (SEC), including Form 20-F and periodic Form 6-K reports that furnish ASX announcements such as clinical trial updates, regulatory developments, and financial results. The company highlights that investors can access ASX and SEC filings, investor and analyst presentations, and other publications through its investor relations channels.

Business model context

Based on Telix’s own descriptions, the company’s business model centers on developing, obtaining regulatory approval for, and commercializing radiopharmaceutical products and related medical technologies. Revenue is associated with sales of approved products such as Illuccix, Gozellix, Scintimun, and SENSEI, while significant resources are allocated to research and development for its pipeline of diagnostic and therapeutic candidates. Telix also references collaborations with partners in areas such as EBRT integration and regional commercialization.

Frequently asked questions (FAQ)